Use of lipid conjugates in the treatment of infection
View Patent ↗This invention provides compounds and methods of use thereof in suppressing, inhibiting, preventing, or treating a pathogenic effect on a cell, including, inter alia, infection with intracellular pathogens. Also provided are compounds and methods of use thereof in suppressing, inhibiting, preventing, or treating an infection in a subject.
1. A method of suppressing, inhibiting, or treating an infection in a subject comprising the step of administering to said subject an effective amount of a lipid conjugate compound, or its pharmaceutically acceptable salt or pharmaceutical product thereof, wherein said compound is represented by the structure of the general formula (I):
wherein
R 1 is a linear, saturated, mono-unsaturated, or poly-unsaturated, alkyl chain ranging in length from 2 to 30 carbon atoms;
R 2 is a linear, saturated, mono-unsaturated, or poly-unsaturated, alkyl chain ranging in length from 2 to 30 carbon atoms;
Y is either nothing or a spacer group ranging in length from 2 to 30 atoms;
X is either a physiologically acceptable monomer, dimer, oligomer or a physiologically acceptable polymer, wherein X is a glycosaminoglycan; and
n is a number from 1 to 1,000;
wherein if Y is nothing the phosphatidylethanolamine is directly linked to X via an amide bond and if Y is a spacer, said spacer is directly linked to X via an amide or an esteric bond and to said phosphatidylethanolamine via an amide bond.
2. The method according to claim 1 , wherein said R 1 and R 2 are myristic acid moieties.
3. The method according to claim 1 , wherein said glycosaminoglycan is chondroitin sulfate.
4. The method according to claim 3 , wherein said chondroitin sulfate is chondroitin-6-sulfate, chondroitin-4-sulfate or a derivative thereof.
5. The method according to claim 1 , wherein said glycosaminoglycan is heparin.
6. The method according to claim 1 , wherein said physiologically acceptable polymer is hyaluronic acid.
7. The method according to claim 1 , wherein said infection is viral.
8. The method according to claim 7 , wherein said infection is mediated by influenza virus.
9. The method according to claim 7 , wherein said infection is mediated by Human Immunodeficiency Virus (HIV).
10. The method according to claim 7 , wherein said infection is mediated by a poxvirus.
11. The method according to claim 1 , wherein said infection is bacterial.
12. The method according to claim 11 , wherein said infection is mediated by Chlamydia.